Daxor’s ezBVA Lab Diagnostic Service Delivers 24-hour Turnaround Under Established Reimbursement Pathways to Support Ambulatory Care Oak Ridge, TN, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced that a major Memphis health system has expanded its Blood Volume Analysis (BVA) program to an additional hospital campus, utilizing Daxor’s ezBVA Lab service to support outpatient clinic testing. The launch buil
Turnkey ezBVA Lab Model Removes Capital Barriers and Leverages Established Reimbursement to Drive Rapid Clinical Adoption. Oak Ridge, TN, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced the commercial launch of a new Blood Volume Analysis (BVA®) program at a leading academic medical center in Kansas, expanding the company’s Midwest footprint and accelerating adoption of its centralized diagnostic service
FDA 510(k)-cleared next-generation diagnostic platform delivers 3x faster results with 50% less blood, setting a new standard for data-driven heart failure management. Key Highlights: Commercial Acceleration: Daxor to feature its FDA-cleared, next-generation Blood Volume Analyzer (BVA™) designed for rapid clinical adoption across hospital systems and outpatient clinicsClinical Evidence: Independent clinical investigators to present two ePosters highlighting how BVA addresses volume derangements
Oak Ridge, TN, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will participate in Lake Street's Tenth Annual Best Ideas Growth (BIG10) Conference in New York City, New York on Thursday, September 10th, 2026. Management will host one-on-one and small group meetings with investors. For more information about the event or questions about registration, interested pa
Oak Ridge, TN, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and President Michael Feldschuh. Dear Valued Shareholders, “It’s still Day 1.” — Jeff BezosThat's exactly how we think about where Daxor stands today. Everything we have accomplished to date — the FDA clearance of our next-generation analyzer, our new patent, our c
This is the newest page. Registered accounts read further back.